Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
Rhea-AI Summary
Alector (Nasdaq: ALEC) will discontinue the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in early Alzheimer’s disease after an independent data monitoring committee found the trial unlikely to meet its primary endpoint.
Alector and GSK will inform participants; full results will be shared at a future medical meeting. Alector says it will continue advancing multiple ABC-enabled programs with IND targets in 2027.
Positive
- Alector will continue advancing multiple ABC-enabled programs after PROGRESS-AD discontinuation
- AL037/AL137 anti-Aβ antibody progressing through IND-enabling studies; IND targeted in Q1 2027
- AL050 engineered GCase ERT for Parkinson’s targeting IND in 2027
- ABC platform supports antibodies, enzymes, and siRNA with peripheral dosing potential
Negative
- Phase 2 PROGRESS-AD of nivisnebart (AL101/GSK4527226) discontinued after IDMC futility finding
- Trial judged unlikely to meet primary endpoint of slowing disease progression at completion
- Co-developed program with GSK will stop enrollment and require participant notifications; full results pending
News Market Reaction – ALEC
On the day this news was published, ALEC gained 3.04%, reflecting a moderate positive market reaction. Argus tracked a peak move of +15.5% during that session. Argus tracked a trough of -24.9% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $8M to the company's valuation, bringing the market cap to $255.36M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Before this news, ALEC was up 1.7% while peers showed mixed moves: FHTX (-0.77%), CAPR (-2.91%), MNPR (+1.17%), OMER (+0.14%), and LCTX flat. No broad biotech pattern explains ALEC’s setup.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 21 | Phase 3 failure | Negative | -49.8% | Latozinemab Phase 3 INFRONT-3 failed clinical endpoints; workforce cut. |
| Apr 17 | Enrollment update | Positive | -6.0% | PROGRESS-AD Phase 2 enrollment completed ahead of schedule in early Alzheimer’s. |
| Nov 25 | Phase 2 failure | Negative | -35.1% | AL002 Phase 2 in early Alzheimer’s failed primary endpoint; program scaled back. |
| Sep 19 | Baseline data | Neutral | +8.9% | Baseline characteristics presented for INFRONT-3 Phase 3 trial in FTD-GRN. |
| Jul 28 | Baseline data | Neutral | -2.0% | Baseline characteristics shared for INVOKE-2 Phase 2 TREM2 agonist trial. |
Clinical trial headlines for ALEC often produced large moves, especially when late-stage trials failed endpoints, with negative outcomes seeing sharp selloffs and even neutral baseline updates sometimes drawing downside reactions.
Over the last two years, Alector’s clinical news has centered on neurodegeneration programs in Alzheimer’s and frontotemporal dementia. A Phase 3 latozinemab trial in FTD-GRN failed clinical endpoints with a -49.84% move, and AL002 Phase 2 in early Alzheimer’s also missed its primary endpoint, triggering a -35.1% reaction. Earlier PROGRESS-AD enrollment completion and baseline-characteristics updates for INFRONT-3 and INVOKE-2 caused more modest mixed moves between about -6% and +9%. Today’s discontinuation of PROGRESS-AD fits this sequence of challenging late-stage readouts in neurodegeneration.
Historical Comparison
Clinical-trial headlines for ALEC have averaged a -16.8% one-day move, with negative Alzheimer’s and FTD readouts often triggering especially sharp declines.
Across same-tag events, Alector advanced multiple neurodegeneration assets into Phase 2 and 3, but several Alzheimer’s and FTD programs failed primary endpoints, prompting workforce reductions and a strategic pivot toward ABC-enabled next-generation candidates.
Regulatory & Risk Context
On March 12, 2026, Alector filed an S-3 shelf registration allowing up to $400,000,000 of securities, including equity and debt. The shelf, which carries forward $308,196,683.14 of unsold securities from a prior registration, creates capacity for future capital raises via prospectus supplements, though no usage has been recorded yet.
Market Pulse Summary
This announcement confirms discontinuation of the PROGRESS-AD Phase 2 trial for nivisnebart after a futility analysis found it unlikely to meet its primary endpoint. It extends a pattern of challenging Alzheimer’s and FTD readouts while management emphasizes ABC-enabled antibodies, siRNA, and enzyme replacement programs targeting INDs around 2027. Investors may track future clinical updates, cash-raising activity under the $400,000,000 shelf, and progress of AL037/AL137, AL050, and AL064 toward IND-enabling milestones.
Key Terms
independent data monitoring committee medical
futility analysis medical
primary endpoint medical
enzyme replacement therapy medical
siRNA medical
blood-brain barrier medical
investigational new drug (IND) regulatory
transferrin receptor medical
AI-generated analysis. Not financial advice.
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint –
--Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer’s disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson’s disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs—
SOUTH SAN FRANCISCO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in individuals with early Alzheimer’s disease (AD) will be discontinued. The decision follows a pre-specified futility analysis conducted by an IDMC, which concluded that the trial was unlikely to meet its primary endpoint of slowing disease progression at completion.
“This outcome is disappointing for patients and families affected by Alzheimer’s disease and underscores the complexity of developing effective treatments for this devastating disease,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “We are deeply grateful to the patients, caregivers, investigators and study staff who participated in the PROGRESS-AD trial and contributed to advancing the scientific understanding of progranulin biology in neurodegeneration. We remain committed to progressing our broader pipeline of programs targeting neurodegenerative disease, including multiple wholly owned candidates enabled by our ABC platform.”
Alector and GSK have been co-developing nivisnebart. The companies will work closely with study investigators to inform participants enrolled in the PROGRESS-AD trial. Full results will be shared at a future medical meeting or congress.
Alector Pipeline Outlook
Alector remains focused on advancing a pipeline of programs designed to treat neurodegenerative diseases through mechanisms that remove toxic proteins, replace deficient proteins, and restore immune and neuronal function. A key pillar of this strategy is Alector Brain Carrier (ABC), the company’s proprietary blood-brain barrier technology platform, which has been developed over the last seven years to enhance brain delivery and enable peripheral dosing across multiple modalities, including antibodies, enzymes, and siRNA.
Alector continues to advance AL037/AL137, its ABC-enabled anti-amyloid beta antibody program for the treatment of Alzheimer’s disease, through investigational new drug (IND)-enabling studies, and is targeting an IND submission in Q1 2027. AL037/AL137 is engineered for robust brain uptake, potency, and safety, incorporating ABC with tuned transferrin receptor binding to facilitate brain penetration and plaque removal while minimizing hematologic effects.
In addition, Alector is advancing its ABC-enabled siRNA platform, which is designed to allow peripheral dosing and potentially more convenient administration compared with traditional intrathecal delivery. AL064/AL164, an ABC-enabled tau-targeting siRNA for Alzheimer’s disease and other tauopathies, is progressing towards IND-enabling studies, while other siRNA programs, ADP062-ABC (alpha synuclein) and ADP065-ABC (NLRP3), continue to move toward lead selection.
The company is also progressing AL050, its ABC-enabled engineered glucocerebrosidase enzyme replacement therapy for Parkinson’s disease, toward an IND application targeted for 2027.
About AL101 / GSK4527226
AL101/GSK4527226 is an investigational human monoclonal antibody designed to block and downregulate the sortilin receptor to elevate progranulin (PGRN) levels in the brain. PGRN, a protein encoded by the GRN gene, regulates lysosomal function, neuronal survival, and inflammation. The protein is genetically linked to multiple neurodegenerative disorders. Alector and GSK have been co-developing AL101 for the potential treatment of early Alzheimer’s disease (AD).
About Alector
Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, research and preclinical pipeline, blood-brain barrier technology platform, planned and ongoing preclinical studies, expected milestones, and expectations of our collaborations. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, with the Securities and Exchange Commission (“SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.
Alector Contacts:
Argot Partners (media)
David Rosen
(646) 461-6387
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
(212) 600-1902
alector@argotpartners.com
